Takhzyro: An Expert’s Perspective

Medically Reviewed by Michelle Vermeulen, PharmD on September 25, 2026

By Jonathan Bernstein, MD,  as told to Sonya Collins

Jonathan Bernstein, MD, is a professor of clinical medicine in the Division of Rheumatology, Allergy and Immunology at the University of Cincinnati College of Medicine in Cincinnati, Ohio, and co-author of the HELP study that led to FDA approval of the drug. The information here represents his knowledge and experience as a medical professional.

Lanadelumab-flyo (Takhzyro) is a prescription monoclonal antibody used for routine prevention of attacks of hereditary angioedema (HAE) in people aged 2 and older. Monoclonal antibodies are lab-made proteins that mimic natural antibodies made by the immune system and target and fight specific disease-causing cells. 

You inject this biologic drug every two to four weeks. Your doctor may prescribe it if you have frequent or severe HAE attacks that rescue medications alone can’t manage.

We talked to Jonathan Bernstein, MD, a professor of clinical medicine in the Division of Rheumatology, Allergy and Immunology at the University of Cincinnati College of Medicine and co-author of the HELP study that led to FDA approval of the drug. 

 

In clinical trials, over 80% of patients responded or had improvement on this drug. It’s FDA-approved for routine prophylaxis to prevent attacks of HAE in patients aged 2 and older — most commonly with HAE types I and II, which are caused by a deficiency or dysfunction in C1-esterase inhibitor. That’s a protective protein in human blood that regulates inflammation, the immune system, and blood clotting. 

It’s generally used in people who have frequent or severe attacks, whose quality of life is significantly disrupted by unpredictable swelling episodes, who have had attacks involving the airway, which is a life-threatening location, or who have not been well controlled on on-demand treatment alone or on other preventive options. When patients are having frequent attacks and they’re having to use rescue medications quite a bit, this would indicate the need to put them on a preventive therapy like lanadelumab. 

Lanadelumab is a fully human monoclonal antibody that works differently from older HAE prophylaxis options that replace the missing or malfunctioning C1-inhibitor protein, as Cinryze and Haegarda do. Lanadelumab is a lab-made antibody that blocks the enzyme plasma kallikrein, preventing it from releasing bradykinin, the molecule that actually causes the swelling in HAE. 

Because it is an antibody with a long half-life [the time it takes for the concentration of a medication in your body to decrease by half], it can be dosed every two weeks, and every four weeks in patients who become attack-free for six months or more, through a subcutaneous injection that patients or caregivers can give at home. That is a practical advantage over C1-inhibitor concentrates, which are typically infused twice weekly, and berotralstat (Orladeyo), which is a daily pill. 

The pivotal Phase 3 HELP study, which included 125 patients aged 12 to 73 with HAE types I and II, found that lanadelumab given every two weeks reduced the average number of monthly attacks by 87%. Given every four weeks, it reduced attacks by 73%. 

It also improved attack severity. It reduced moderate-to-severe attacks by 83% and attacks requiring rescue treatment by 87%. A meaningful share of patients were completely attack-free during the study. 

Effects are seen fairly early — within the first month of treatment. Long-term data, following patients for well over two years, support that the effect is sustained rather than wearing off over time.

 

Yes, lanadelumab is generally considered safe. It doesn’t carry an FDA boxed warning. Long-term studies that have included several years of follow-up continue to support a favorable safety profile. As with any biologic, the main safety consideration is hypersensitivity or allergic reaction, which is uncommon but possible.

The most common side effect is an injection site reaction, such as pain, redness, or bruising, reported in roughly half of patients in trials, though these are usually mild and temporary. Other reactions include upper-respiratory symptoms such as a stuffy nose or sore throat, headache, dizziness, diarrhea, rash, and muscle aches. 

You may be able to prevent injection site reactions by letting the prefilled syringe warm to room temperature before injecting; rotating injection sites between the abdomen, thigh, and upper arm; and using a cold compress afterward if the area is sore. Patients should seek immediate medical attention for signs of a serious allergic reaction, such as hives, difficulty breathing, or swelling of the face, lips, or tongue, though these are rare.

There is no mandated lab-monitoring program for lanadelumab, so it does not require the kind of routine blood tests some biologics do. Patients only need periodic follow-up with the prescribing specialist to track attack frequency and severity, injection technique, and overall symptom control — similar to what’s needed with other chronic biologic therapies.

The only formal contraindication is you have a known hypersensitivity to lanadelumab-flyo or any of its ingredients. It also has not been established as safe or effective in children under age 2. 

Data in pregnancy and breastfeeding are limited. Antibodies like this one can cross the placenta, particularly in the third trimester. It is unclear whether it is excreted into breast milk in humans, though studies in animals suggest very low transfer. Use during pregnancy or lactation is generally a shared decision between patient and physician, weighing risks and benefits. 

No significant drug-drug interactions have been identified in formal studies. Common analgesics, antibiotics, antihistamines, and rescue HAE medications do not appear to affect it.

Lanadelumab is an expensive specialty biologic. The list price for a single 300 mg/2 mL prefilled syringe is around $25,000. At the standard every-two-week dosing schedule, or about 26 doses a year, that works out to a list price well into the hundreds of thousands of dollars annually before any insurance or manufacturer discounts, broadly in line with other HAE prophylactic biologics. 

Most commercial insurers, Medicare, and Medicaid cover it given its orphan-drug status and the lack of good alternatives for many patients, though prior authorization is typically required, which takes a lot of effort on the part of the physician. 

Takeda, the manufacturer, offers a patient support program that can cover up to 100% of out-of-pocket copay costs for eligible commercially insured patients, up to $40,000 per year in assistance, plus separate assistance pathways for uninsured or underinsured patients based on income tied to federal poverty level guidelines. 

This is a decision best made together with an allergist or immunologist experienced in HAE, ideally at an HAE specialty center, weighing the specific patient's attack pattern and life circumstances against the available options.

The key factors include how often and how severely attacks occur. They may have only four attacks a year, but the attacks affect their throat. If they’re having throat swells and they’ve been intubated, that’s an indication for this medication. If someone is having two to three attacks a month and they have to use their rescue medicine, that’s another indication. If they’re going to the emergency room a lot or being hospitalized, that’s an indication. 

You have to look at how much the attacks affect daily life, including work and school. You need to consider whether the patient or caregiver is comfortable with self-administered injections every two to four weeks. You also have to look at response to prior preventive treatments. You need to take into account whether the patient is pregnant or breastfeeding or plans to become pregnant, alongside practical considerations like ability to keep the medication refrigerated and insurance coverage and cost given the price of the drug. 

The foundational evidence is the phase 3 HELP study, a randomized, double-blind, placebo-controlled, dose-ranging trial in 125 patients that led to lanadelumab’s initial FDA approval in 2018. The extension study followed patients for over two-and-a-half years and confirmed ongoing efficacy and safety over the long term. The phase 3 SPRING study extended this evidence to children ages 2 to under 12, supporting the 2023 FDA approval expanding Takhzyro's use to that younger age group. Ongoing phase 4 real-world studies have continued to support its effectiveness outside the controlled trial setting. 

Add WebMD as a Preferred Source to see more of our trusted content across Google Search, AI Overviews, and AI Mode